Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) have been assigned an average recommendation of “Moderate Buy” from the five brokerages that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $8.3333.

A number of research firms have recently weighed in on AUTL. Wall Street Zen cut Autolus Therapeutics from a “hold” rating to a “strong sell” rating in a report on Saturday, November 15th. William Blair restated an “outperform” rating on shares of Autolus Therapeutics in a report on Wednesday, September 24th. Needham & Company LLC reiterated a “buy” rating and set a $10.00 price target on shares of Autolus Therapeutics in a report on Monday, November 3rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Autolus Therapeutics in a research report on Wednesday, October 8th. Finally, Wells Fargo & Company decreased their target price on shares of Autolus Therapeutics from $6.00 to $5.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 13th.

Hedge Funds Weigh In On Autolus Therapeutics

Several institutional investors have recently added to or reduced their stakes in AUTL. Cetera Investment Advisers boosted its stake in Autolus Therapeutics by 47.3% in the 1st quarter. Cetera Investment Advisers now owns 524,872 shares of the company’s stock worth $814,000 after buying an additional 168,650 shares during the last quarter. Privium Fund Management B.V. lifted its holdings in shares of Autolus Therapeutics by 8.6% during the 1st quarter. Privium Fund Management B.V. now owns 251,674 shares of the company’s stock worth $390,000 after acquiring an additional 20,000 shares during the period. Invesco Ltd. boosted its position in shares of Autolus Therapeutics by 53.3% in the first quarter. Invesco Ltd. now owns 32,738 shares of the company’s stock worth $51,000 after acquiring an additional 11,381 shares during the last quarter. Knott David M Jr acquired a new stake in shares of Autolus Therapeutics in the first quarter worth approximately $651,000. Finally, Wellington Management Group LLP grew its holdings in Autolus Therapeutics by 6.9% in the first quarter. Wellington Management Group LLP now owns 27,091,700 shares of the company’s stock valued at $41,992,000 after purchasing an additional 1,746,020 shares during the period. 72.83% of the stock is currently owned by institutional investors and hedge funds.

Autolus Therapeutics Price Performance

Shares of NASDAQ AUTL opened at $1.41 on Monday. The firm’s 50-day moving average is $1.49 and its two-hundred day moving average is $1.80. The company has a market capitalization of $375.26 million, a PE ratio of -1.70 and a beta of 1.84. Autolus Therapeutics has a 12-month low of $1.11 and a 12-month high of $3.45.

Autolus Therapeutics (NASDAQ:AUTL) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.07). The company had revenue of $21.19 million for the quarter, compared to analyst estimates of $21.08 million. Autolus Therapeutics had a negative return on equity of 63.76% and a negative net margin of 439.69%. On average, analysts forecast that Autolus Therapeutics will post -0.94 EPS for the current fiscal year.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.